(MedPage Today) -- An investigational heart failure drug being developed by Novartis cut deaths from heart disease by 20% compared with standard therapy, researchers reported today at the European Society of Cardiology. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment